{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:30:46Z","timestamp":1793755846529,"version":"4.6.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":40,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.rpth.2025.102860","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T19:44:38Z","timestamp":1744919078000},"page":"102860","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Management of bleeding and invasive procedures in patients treated with anti\u2013factor XI(a) anticoagulants: proposals from the French Working Group on Perioperative Haemostasis and French Society of Thrombosis and Haemostasis"],"prefix":"10.1016","volume":"9","author":[{"given":"Anne","family":"Godier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Lasne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne\u2013C\u00e9line","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Pernod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Albaladejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"De Maistre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lecompte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9goire","family":"Le Gal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerrold H.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Mazighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Mullier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Roullet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Schved","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Si\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Normand","family":"Blais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Gouin-Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Susen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2025.102860_bib1","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/jth.13342","article-title":"Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway","volume":"14","author":"Colucci","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102860_bib2","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1182\/bloodadvances.2017015123","article-title":"Abnormal plasma clot formation and fibrinolysis reveal bleeding tendency in patients with partial factor XI deficiency","volume":"2","author":"Gidley","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2025.102860_bib3","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1182\/blood.2023020722","article-title":"Targeting factor XI and factor XIa to prevent thrombosis","volume":"143","author":"Gailani","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.102860_bib4","doi-asserted-by":"crossref","first-page":"49323","DOI":"10.1074\/jbc.M407889200","article-title":"Factor XI interacts with the leucine-rich repeats of glycoprotein Ib\u03b1 on the activated platelet","volume":"279","author":"Baglia","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.rpth.2025.102860_bib5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/rth2.12162","article-title":"Polyphosphate in thrombosis, hemostasis, and inflammation","volume":"3","author":"Baker","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102860_bib6","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1182\/blood.V91.10.3800","article-title":"Tissue-specific expression of functional platelet factor XI is independent of plasma factor XI expression","volume":"91","author":"Hu","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.102860_bib7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/jth.15579","article-title":"A proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors","volume":"20","author":"Salomon","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102860_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus apixaban in patients with atrial fibrillation","volume":"392","author":"Piccini","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.102860_bib10","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2025.102860_bib11","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(23)00403-9","article-title":"Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial","volume":"23","author":"Sharma","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.rpth.2025.102860_bib12","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/eurheartj\/ehad123","article-title":"Reversal agents for current and forthcoming direct oral anticoagulants","volume":"44","author":"Van Es","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rpth.2025.102860_bib13","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jtha.2024.07.009","article-title":"Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH","volume":"22","author":"Levy","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102860_bib14","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/ejh.13941","article-title":"Management of rare inherited bleeding disorders: proposals of the French Reference Centre on Haemophilia and Rare Coagulation Disorders","volume":"110","author":"Trossaert","year":"2023","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.rpth.2025.102860_bib15","doi-asserted-by":"crossref","first-page":"6314","DOI":"10.3390\/jcm11216314","article-title":"Clinical pharmacology of factor XI inhibitors: new therapeutic approaches for prevention of venous and arterial thrombotic disorders","volume":"11","author":"Campello","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.rpth.2025.102860_bib16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.thromres.2017.12.023","article-title":"Assessment of two contact activation reagents for the diagnosis of congenital factor XI deficiency","volume":"163","author":"Salloum\u2013Asfar","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2025.102860_bib17","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jth.15588","article-title":"Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: in vitro studies and in vivo evaluation in experimental thrombosis in rabbits","volume":"20","author":"Wong","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102860_bib18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/ijlh.14002","article-title":"How to assess parallelism in factor assays: coefficient of variation of results with different dilutions or slope ratio?","volume":"45","author":"Guy","year":"2023","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.rpth.2025.102860_bib19","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/jth.15700","article-title":"Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa","volume":"20","author":"Heitmeier","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102860_bib20","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-10-880849","article-title":"MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans","volume":"133","author":"Koch","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.102860_bib21","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1016\/j.jmb.2019.09.008","article-title":"Allosteric inhibition as a new mode of action for BAY 1213790, a neutralizing antibody targeting the activated form of coagulation factor XI","volume":"431","author":"Schaefer","year":"2019","journal-title":"J Mol Biol"},{"key":"10.1016\/j.rpth.2025.102860_bib22","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.jtha.2025.02.025","article-title":"Anticoagulants targeting factor XI\/XIa and coagulation tests: we urgently need reliable pharmacodynamic data","volume":"23","author":"Gouin\u2013Thibault","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102860_bib23","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1365-2516.2006.01304.x","article-title":"Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy","volume":"12","author":"Salomon","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.102860_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102199","article-title":"Surgery in rare bleeding disorders: the prospective MARACHI study","volume":"7","author":"Rousseau","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102860_bib25","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/bjh.13058","article-title":"Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors\u2019 Organization guideline on behalf of the British Committee for Standards in Haematology","volume":"167","author":"Mumford","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2025.102860_bib26","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1055\/s-0039-1696685","article-title":"Single low dose of rFVIIa combined with antifibrinolytic agent is a simple and safe treatment for factor XI-deficient patients undergoing surgery","volume":"119","author":"Salomon","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102860_bib27","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/hae.12655","article-title":"Factor XI replacement for inherited factor XI deficiency in routine clinical practice: results of the HEMOLEVEN prospective 3-year postmarketing study","volume":"21","author":"Bauduer","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.102860_bib28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.thromres.2023.05.003","article-title":"OKL-1111, a modified cyclodextrin as a potential universal reversal agent for anticoagulants","volume":"227","author":"Meijers","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2025.102860_bib29","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1111\/bcp.15230","article-title":"Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: a randomized phase 1 multiple-dose study","volume":"88","author":"Kubitza","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.rpth.2025.102860_bib30","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1038\/s41598-022-08768-y","article-title":"Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants","volume":"12","author":"Perera","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.rpth.2025.102860_bib31","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/cts.13148","article-title":"First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor","volume":"15","author":"Perera","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.rpth.2025.102860_bib32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.kint.2024.02.024","article-title":"A phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis","volume":"106","author":"Winkelmayer","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.rpth.2025.102860_bib33","article-title":"Guidelines for the management of anticoagulants in emergency settings","author":"Douillet","year":"2025","journal-title":"ACCPM"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925001840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925001840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T16:19:34Z","timestamp":1761841174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037925001840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2475037925001840"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2025.102860","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of bleeding and invasive procedures in patients treated with anti\u2013factor XI(a) anticoagulants: proposals from the French Working Group on Perioperative Haemostasis and French Society of Thrombosis and Haemostasis","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2025.102860","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102860"}}